Active substance
Lornoxicam
- SFDA 13
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EXXARA 8 mg film-coated tablets | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 17.50 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| KALMO 8MG F.C.TABLET | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 15.75 | Generic · Prescription | Al-Taqaddom pharmaceutical Industries | Valid |
| Kalmo | 8 mg | Film-coated tablet · Oral use | 30 Blister | SAR 23.60 | Generic · Prescription | Al-Taqaddom pharmaceutical Industries | Valid |
| LEROXO 8 MG FILM COATED TABLET | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 17.50 | Generic · Prescription | UNITED PHARMACEUTICAL CO. | Valid |
| Lornoxicam- GPI | 8 mg | Powder and solvent for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 13.70 | Generic · Prescription | Global Pharmaceutical Industries | Valid |
| OXIRA 8MG F.C.TABLET | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 17.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| OXIRA RAPID | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 19.25 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| XEFO 8MG Powder for injection | 8 mg | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 18.35 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| XEFO 8MG TAB | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 23.95 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Xelorni 8 mg F.C.TABLET | 8 mg | Film-coated tablet · Oral use | 30 Blister | SAR 23.60 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| ZENORIT 8 mg film-coated tablets | 8 mg | Film-coated tablet · Oral use | 20 Blister | SAR 19.45 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| ZENORIT 8 mg lyophilisate for solution for injection | 8 mg | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 14.40 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| OXIRA 4MG F.C.TABLET | 4 mg | Film-coated tablet · Oral use | 20 Blister | SAR 8.75 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; LOW BACK PAIN; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.